Abstract 1527
Background
Cancer patients in good general condition can receive aggressive anti-cancer treatment, while palliative care is most appropriate for advanced cancer patients. In China, patients admit to 3A hospitals regardless of the disease stage. Given the limited number of 3A hospital beds, high price, low quality of life, family sickbed is emerging. With one-to-one help of The Second Affiliated Hospital of FMU, Dongshi Township Health Center (DTHC) established the first family sickbed project for oncology patients (FSOP) in China.
Methods
A retrospective survey was adopted to analyze the general clinical data of patients, hospitalization days and expenses, the types of medical insurance and the opioid analgesics drugs used of 225 patients. And, we carried out telephone follow-up to collect the data concerning the patient’s survival and satisfaction with FSOP service.
Results
From 2015 to 2017, 225 patients were admitted to FSOP. Of 225 patients, 192 (85.3%) were males and 33 (14.7%) were females with ages from 24 to 91 years. The most common disease categories were lung cancer, esophagus cancer, liver cancer. 216 out of 225 patients purchased the NCMS Insurance. During those 3 years, the average total hospitalization expenses, the average personal expenses, the average personal expenses ratio, the average reimbursement ratio, and the average hospitalization days of all patients were 3824.24yuan, 1195.34yuan, 34.64%, 65.37% and 11.79 days, respectively. 51 out of 225 patients suffered pain and needed to eat painkillers. The use of Morphine tablets and OxyContin increased year by year, conforming to the principle of the WHO’s three-step analgesic ladder. Follow-up results showed that 37 (18.5%, 37/200) patients were survive, and 177 patients or family members (88.5%, 177/200) were fully satisfied with FSOP’s service.
Conclusions
Since 2015, the DTHC has provided considerate home care, resulting in a high level of patient and family members satisfaction. Admitting to FSOP can lower the hospitalization expenses, decrease the burden of economy and life, improve the quality of life, and relieve the pain, both mental and physical. Moreover, FSOP will be a more appropriate place to spend the last days for advanced cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Second Affiliated Hospital of Fujian Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract